Showing 5261-5270 of 5909 results for "".
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M
- Nicox Updates on Zerviate Progress in China and Expands the Countries of its Agreement with Ocumension Therapeuticshttps://modernod.com/news/nicox-updates-on-zerviate-progress-in-china-and-expands-the-countries-of-its-agreement-with-ocumension-therapeutics/2477370/Nicox SA announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in
- AAD Annual Meeting Becomes Latest Casualty of COVID-19 Outbreakhttps://modernod.com/news/aad-annual-meeting-becomes-latest-casualty-of-covid-19-outbreak/2477371/The American Academy of Dermatology (AAD) annual meeting became the latest casualty of the COVID-19 outbreak, with the conference cancelled on Tuesday. The meeting was scheduled to be held from March 20 to 24
- Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucomahttps://modernod.com/news/sight-sciences-announces-publication-of-first-ever-multicenter-migs-study-in-childhood-glaucoma/2477366/Sight Sciences announced that positive outcomes from a new multicenter study of one of the OMNI Surgical System’s predecessor devices, TRAB360, were published in the
- Analysts Give Gilead’s Remdesivir 50% Chance of Success as COVID-19 Treatmenthttps://modernod.com/news/analysts-give-gileads-remdesivir-50-chance-of-success-as-covid-19-treatment/2477362/Analysts at RBC Capital Markets suggested that it is a toss-up whether Gilead Sciences’ remdesivir will succeed in demonstrating efficacy and ultimately securing approval to treat COVID-19, citing limited dosing results, confounding data and previous disappointments in Ebola. “[The] b
- Jim Mazzo Receives the Ellis Island Medal of Honorhttps://modernod.com/news/jim-mazzo-receives-the-ellis-island-medal-of-honor/2477358/Jim Mazzo, Global President of Ophthalmic Devices with Carl Zeiss Meditec, has been chosen to receive the Ellis Island Medal of Honor in 2020. The Ellis Island Honors Society honors the importance of immigration to America’s prosperity and celebrates the contributions immigrants and their
- PRISM Vision Group Announces Agreement With The Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington-2/2477356/PRISM Vision Group announced an agreement to add its newest partner, The Retina Group of Washington (RGW), a provider of retinal and macular care in Washington, D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us and over the past sever
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 Genetic Modifier to Treat Retinitis Pigmentosahttps://modernod.com/news/nature-gene-therapy-publishes-preclinical-data-of-ocugens-ocu400-genetic-modifier-to-treat-retinitis-pigmentosa/2477345/Ocugen announced the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designatio